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doi:10.1016/j.ejvs.2009.10.018Abstract This prospective study aims to evaluate the impact of the excimer laser technology
as the first-line endovascular treatment of critical limb ischaemia (CLI) in diabetic patients.
The protocol allowed the use of laser ablation of obstructive lesions when conventional endo-
luminal guidewire crossing of the plaque was unsuccessful. We extrapolate the data of consec-
utive patients treated, who completed at least 12 months of follow-up, extending the
observation to a 26-month time frame. During this period, 67 diabetic patients with CLI were
brought to the Cath Lab for ‘operative angioplasty’ and to be treated with endovascular tech-
niques. Of the 67 cases, laser was used on 35 patients to treat 51 lesions. All patients had type
C or D occlusive lesions, according to the TACS II classification, showing a single type D plaque
or multiple tandem C/D occlusive plaques ranging from 4 to 23 cm in length. The immediate
clinical success, defined as restored direct arterial flow to the foot, was 88.2%. The lesions
were successfully crossed by laser in 45 out of 51 attempts. Stents were required in 25% of
the patients with 21% lesions. Patency rates were assessed using the KaplaneMeier survival
curves. The patency rates of the successfully treated lesions (freedom from target lesion re-
vascularisation) were 96.6% at 12 months and 82.7% at 24 months. Limb-salvage rate at 12
and 24 months were 100% and 94%, respectively. Our study showed that the excimer laser-support to the study or the analysis by the companies involved in the technology used in this study.
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Excimer Laser for CLI in Diabetics 235assisted angioplasty, when feasible, is effective in granting event-free survival in CLI patients
with diabetes, and that endoluminal-driven atherectomy allows long-term success in reducing
the need of stents in the lower limb arteries.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
The idea of using laser energy to treat vascular obstruction
dates back almost 30 years.1,2 Early attempts failed in
gaining proper diffusion: the technology used at that time
relied on a complicated system to generate laser beams in
a broad, higher-wavelength spectrum (argon to CO2 or
Ho:YAG), which is mainly absorbed by haemoglobin. Laser
atherectomy at this wavelength was accomplished through
direct action or by heating a metallic tip to induce vapor-
isation of the tissue. It was difficult with such technology to
control and limit the heat to the plaque alone and to avoid
energy transfer and damage to the rest of the vessels and
their surrounding tissues.3,4 This method of laser applica-
tion in peripheral arterial diseases was eventually aban-
doned. The evolution of excimer laser technology
(Spectranetics Corporation, Colorado Springs, CO, USA)
revived the use of laser in vascular applications. The exci-
mer laser is based on a cold-tipped laser that delivers
intense bursts of energy in the ultraviolet range (308 nm)
carried out in ultra-short pulse durations (0.05 mm per
pulse vs. 0.3e2.0 mm per pulse in the hot-tip laser). The
energy delivered in this way elicits photochemical, photo-
thermal and photomechanical actions, which break
molecular bonds, and produce vapour bubbles that
generate kinetic energy. The excimer laser application has
been studied in long total superficial femoral artery (SFA)
occlusions (The Peripheral Excimer Laser Angioplasty
(PELA) trial) as well as the below-the-knee lesions for CLI
patients e with improved results over standard percuta-
neous transluminal angioplasty (PTA) alone e and exhibited
excellent limb-salvage rates.5e7 The major advantage of
the excimer laser probe with respect to other mechanical
atherectomy devices is its ability to debulk in a ‘step-by-
step’ fashion. The guidewire closely follows the track
created by the laser collimate beams without the need of
its previous passages. The use of the excimer technology
represents a great opportunity to pursue a true endolumi-
nal recanalisation with potentially longer-term efficacy and
a decreased need for stenting. The LACI 2 and the LACI
Belgium studies have both proven that laser-assisted
angioplasty is a low-risk, successful treatment strategy in
patients with CLI.6,7 Noting the high percentage of dia-
betics in both studies (66% in LACI 2 and 47% in LACI
Belgium) we wanted to specifically look into the laser
angioplasty option for this subgroup of high-risk surgical
patients. We created an ongoing registry to evaluate the
long-term effectiveness of endovascular procedures. Our
institution acquired laser technology in January 2007 and
shortly after, we created a non-randomised prospective
study to analyse the impact of the excimer laser-assisted
PTA in infra-inguinal arteries of CLI patients with diabetes.To contain costs, we chose to use the laser properties
mainly to break the plaque cup of obstructive lesions when
attempts by wiring were unsuccessful in gaining endolumi-
nal recanalisation. The purpose of this analysis is to provide
evidence of the long-term efficacy of the excimer laser
treatment in this subgroup of diabetics with CLI.
Materials and methods
The data presented in this article are extrapolated from
a prospective clinical registry created to monitor the
outcomes of endovascular procedures in patients with
diabetes mellitus type 2 and evidence of CLI, as defined by
TASC I and II guidelines (rest pain or non-healing ulcerative
lesions or gangrene, Rutherford Category 4e6). The
prospective clinical registry included consecutive diabetic
patients with CLI. For this study we extrapolated the data
of patients who had completed 12 months of follow-up by
the time of the analysis and restricting the observation to
26 months. Our clinical protocol of first-line endovascular
approach to CLI in diabetic patients is based on ‘operative
angiography’ meaning that patients were first evaluated by
Doppler ultrasound study and then brought to the angiog-
raphy suite where endovascular attempts at revascularisa-
tion were made. Patients were candidates for laser
revascularisation when there was radiographic evidence of
total occlusive lesion of the first of targeted lesions to be
crossed and simple conventional guidewire advancement
failed in securing endoluminal recanalisation. The primary
end-points of the registry were ‘procedural success’,
defined as restitution of a straight-line flow to the foot and
‘efficacy end-points’ at defined timescales; patency of the
treated segment, absence of reintervention, wound healing
and salvage of the treated limb defined as the absence of
major amputation, that is, an amputation of the treated
limb at or above the ankle. The incidences of minor
amputations were recorded and considered successful if
they did not impair the functionality of the feet.
Standard endovascular techniques were carried out:
percutaneous access to the common femoral artery was
obtained in all patients. The contralateral crossover
approach was preferred in most cases. The preferred
technique was endoluminal recanalisation, directly crossing
the obstruction with the guidewire and/or catheters
avoiding the intentional subintimal way. A guidewire was
used to negotiate the occlusion as a first attempt followed
by PTA or stenting. If the guidewire was not able to
recanalise the obstruction, direct laser impulse was used to
break the plaque cup and a step-by-step technique was
conducted in which upfront laser ablation was followed by
the guidewire advancement in a sequential manner, up to
complete recanalisation of the obstruction. Lesions were
Table 2 Arterial lesion sites.
Lesion site N
(totalZ 51)
Lesion length
range in cm
%
Iliac artery 3 4e8 5.9
Superficial femoral
artery
25 10e23 49.0
Femoral profundus 1 2 2.0
Popliteal artery P1/P2 4 4e8 7.8
Popliteal artery P3 4 3e5 7.8
Anterior/posterior
tibial artery
9 6e16 17.6
Interossea artery 2 8,14 3.9
Tibioperoneal artery 3 2,4,4 5.9
(Restenotic lesions) 6 11.8
45 41 20
19
11
0.
75
1.
00
Primary patency rate
236 F. Serino et al.further treated with excimer laser ablation using larger
catheters, unless satisfactory debulking had already been
achieved by the step-by-step technique. Laser catheters of
sizes between 0.9 and 2.5 mm were used. In three cases the
Turbo Booster directional catheter was used to achieve
complete ablation of the lesions. Following laser ablation,
a low-pressure balloon PTA was generally used to optimise
vessel inner diameters. Stents were implanted only in case
of suboptimal results due to recoil, dissection or accidental
subintimal channelling. A successful procedure was
concluded by the achievement of straight-line flow from
the pelvic arteries through at least one tibial artery to the
pedal arteries of the foot. Anticoagulation therapy was
administered to all patients with 150 mg of clopidogrel per
oral (p.o.) 1 day prior to surgery and heparin (5000 UI)
intravenous (IV) during the endovascular procedure. The
maintenance of anticoagulation with 100 mg of aspirin and
75 mg of clopidogrel (p.o.) per day for 3 months were
recommended postoperatively.
Patency rates were assessed using the KaplaneMeier
survival curves. The computer package STATA 9 (Stata Corp,
College Station, TX, USA) was used for statistical analyses.
The methodology of the study and data extrapolation
were authorised by the local Ethics Committee.
Results
Restricting the observation to patients who had completed
a year of follow-up within 26 months, it was found that 67
diabetic patients, who were brought in for endovascular
procedures for CLI, had obstructive lesions to be chal-
lenged. In 32 patients, the obstructive (single or sequential)
lesions were successfully crossed with the wiring tech-
nique. The excimer laser was used on 35 patients to treat
51 chronic total occlusions. The study sample included
a total of 35 patients with a mean age standard deviation
(SD) of 67.1 years 12.2 (median 68 years, range 27e89
years). Of these, 68.6% patients were male. The patients’
clinical characteristics are shown in Table 1. Patients were
followed up with clinical assessments and Doppler ultra-
sounds at 1,3,6,12,18 and 24 months. A total of 51 lesions
were treated, with a mean number of 1.5 lesions per
patient (range: 1e3 lesions). All cases fitted in the TASC C
or D category, being total occlusions and ranging between 4
and 23 cm of length. The most frequent lesions concerned
the SFA (nZ 25; 49%), the anterior tibial artery (nZ 9;
17.6%) and the popliteal artery (nZ 8; 15.7%) (Table 2).
Turbo Elite catheters were used, mainly the 0.9- and 1.4-Table 1 Clinical characteristics of patients.
N (totalZ 35) %
Hypertension 27 77.1
Dyslipidemia 20 57.1
Coronary artery disease 16 45.7
Chronic renal insufficiency 5 14.3
History of other diseasesa 7 20.0
History of stroke 2 5.7
Smoking 10 28.6
a COPD, liver cirrhosis and cancer.mm catheters in the tibial or tibioperoneal vessels and the
1.7-, 2- and 2.5-mm catheters in the femoral and popliteal
segments. Probes were used singularly or in upgrading
progression according to the diameter of the reference
vessel and efficacy in debulking. Proper lumen sizing and
wall was generally assured by angioplasty using long
(8e15 cm) balloons. The immediate clinical success rate,
defined as restored direct arterial flow to the foot was
88.2%, with five cases and six lesions of failure of recanal-
isation, mostly because of major plaque calcifications
leading to subintimal routing or perforation. In these six
failures in laser recanalisation, treatment was continued
where possible with alternative endovascular techniques
(subintimal angioplasty). Therefore, 30 patients and 45
lesions entered the follow-up programme. Stents were
required in 21.0% of the lesions for flow-limiting dissection
(seven lesions) and recoil (four lesions) accounting for 25%
of the limbs. Balloon dilatation was required to complete
angiographic results in 64.0% of all cases and 100% of tibial
recanalisations using specifically designed balloon cathe-
ters (Amphirion, Invatec SpA, Italy and Savy Long, Cordis,
CO, USA). Patency rates were assessed using the Kaplane
Meier survival curves. The patency rates were (freedom
from target lesion revascularisation) 97.6% at 12 months
and 82.7% at 24 months (Fig. 1).0.
00
0.
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Figure 1 Patency rates expressed by the KaplaneMeier
curve, with numbers at risk at the beginning of each time
interval.
Excimer Laser for CLI in Diabetics 237Limb-salvage rate at 6 and 12 months were 100% and
94%, respectively. Minor amputation, defined as an ampu-
tation of the distal or the mid-foot, leaving the patient with
an ambulatory foot, was required in 6.7% of patients
throughout the follow-up period. Endovascular reinterven-
tion was required in two patients because of clinically
significant restenosis. Ulcer improvements were observed
in all patients with immediate surgical success. Two
patients needed major amputations.
None of the patients enrolled died.Discussion
The basic concept of laser atherectomy is well described in
literature. The key feature of laser atherectomy is the
ability to debulk and ablate tissue (thrombus or plaque)
without damaging the surrounding tissue, thus minimising
restenosis. Lasers suitable for intravascular use produce an
intense monochromatic light beam through fibre optic
catheters that can be delivered to a specific area of the
tissue. The excimer laser employs precise energy control
(shallow tissue penetration) and safer wavelengths thereby
decreasing perforation and thermal injury to the treated
vessels. The ‘Cool’ excimer Xeno/Chlorum (Xe/Cl) laser
produces a light of 308 nm wavelength, which ablates on
a photochemical, rather than a thermal, level. The ultra-
violet light provides a direct lytic action that ablates 5 mm
of tissue on contact without a rise in surrounding tissue
temperature. The advantage of using UVB light lies in its
ability to break molecular bonds directly by a photochem-
ical process.
To use pulsed lasers, such as the Xe/Cl excimer laser,
successfully, the thermal effect must be confined to the
irradiated tissue. That is, the laser pulse must deliver its
energy in a time span much shorter than it takes for the
heat to diffuse away from the tip of the catheter. Once
thermal confinement is assured, tissue ablation can be
achieved by forcing the tissue to absorb enough energy in
one pulse to vaporise the most volatile liquid in the cell’s
water. This is accomplished by transmitting sufficient
energy per pulse, through each fibre in the catheter, to
ensure that the water content of the tissue in the thermal
confinement zone under each fibre vaporises. With the Xe/
Cl laser, the cell structures are first weakened by photo-
chemical bond breaking and then the cells explode when
their internal water turns into steam.
This leaves sub-cellular debris and a shallow crater
under the catheter. The debris washes downstream without
embolising distal capillaries and the catheter tip advances
into the crater.
On the next laser pulse, the process repeats, allowing
the catheter tip to nibble through the tissue, as each laser
pulse removes a thin layer of tissue at the bottom of the
crater.
The success of excimer laser-assisted angioplasty in the
lower limbs are documented in the previously published
studies, including the LACI phase 2 and the LACI Belgium
studies.6,7 The LACI 2 was a clinical study that evolved from
a 25-patient phase 1 registry enrolling 145 patients with
CLI. Straight-line flow to the foot was restored in 89% of the
patients, with adjunctive PTA and stenting in 96% and 45%of cases, respectively. The patency rate at 6 months was
83%. The 6-month limb-salvage rate was 92.5% with a major
amputation rate of 8%. The LACI Belgium study involved 48
patients with CLI. Straight-line flow to the foot was
restored in majority of the patients, with adjunctive PTA
and stenting in 80% and 52.9% of the cases. The patency
rate at 6 months was 76%. The 6-month limb-salvage rate
was 90.5% with a major amputation rate of 8%.
Compared with the LACI studies, our registry showed
similar lesion sites in patients exclusively with diabetes.
The other clinical characteristics of our patients were
typical of those with systemic vascular diseases and were
very similar to the two LACI studies. The LACI 2 and the
LACI Belgium studies included only patients who are poor
surgical candidates. Our laser endovascular registry
included all patients (with diabetes) who are candidates for
peripheral revascularisation procedures. This lower degree
of co-morbidities of our patients may partly explain the
fact that our patency rates as well as limb-salvage rates at
different timescales were better than those shown in both
the LACI trials. The reduced use of stents, fewer patients,
a different selection criteria and a single centre (compared
with multicentre) activity may also explain these
differences.
The increasing success in recent times with the endo-
vascular approach to diabetic patients with CLI is pushing
towards an extension of indication to endovascular recan-
alisation in the early stages of diabetic arteriopathy. This
tendency should, in our opinion, be justified a technology
that could potentially give more durable results than the
ones seen by PTA and stenting.
Atherectomy offers a theoretical advantage with respect
to balloon angioplasty as a primary rechanneling technique
based on the premise that the ablation effect allows
remodelling of the vessel lumen without excessive
stretching of the vessel. Our personal experience and the
other published results of mechanical atherectomy (Rota-
blator or Silver Hawk) support this assumption,8,9
showing good long-term patency and limb-salvage rates.
It is still uncertain if stents, in general, improve or
jeopardise the results of angioplasty,10 especially with
regard to the long-term results of endovascular interven-
tion. In diabetic patients, the incidence of in-stent reste-
nosis is thought to be higher than that of non-diabetics.
From this aspect, plaque ablation may allow better results
of angioplasty and reduce the need for stenting, although
this was not proven in the LACI 2 trial (45% of the cases)6
and LACI Belgium trial (52.9%).7
The patency rates as well as limb-salvage rates in our
report are superior to those reported in standard angio-
plasty11 and angioplasty with stent.12 They are comparable
with those published in large series of diabetic populations,
even under different criteria of CLI classification.13,14
Cost is one of the drawbacks of laser technology. Even if
cost analyses are not comparable, being variable among
centres and regions and related to the use, we assessed
that costs of laser technology are superior to that of stan-
dard technology. In our experience, costs range between
3500 and 4800 euros per procedure, depending on the
number of probes needed. In our centre, these costs fall
into the corresponding DRG compensation and certainly
below the ‘ethic’ threshold of the amputation.
238 F. Serino et al.Conclusions
Our study is based on a monocentric registry and is limited
to a small sample of patients. However, the population is
homogeneously diabetic, which marks a significant differ-
ence with similar published observations, suggesting that
our contribution could be of some relevance in this field. In
particular, we feel that our experiences confirm that the
excimer laser-assisted angioplasty is effective as the first-
line endovascular treatment of CLI in diabetic patients.
Mid- and long-term results are extremely promising and are
in line with the other published data of laser and
mechanical atherectomy techniques, suggesting that pla-
que debulking may have an impact on avoiding restenosis or
re-occlusion of the treated segments. Unlike other
comparable published studies, we showed that endolumi-
nal-driven atherectomy allows long-term success, reducing
the need for stents. We believe that large comparative
studies addressing this aspect should be encouraged.
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